Prot #SHP-141-003: A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients with Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date11/17/14 → 11/17/17

Funding

  • INC Research, LLC (Prot #SHP-141-003 // Prot #SHP-141-003)
  • TetraLogic Pharmaceuticals Corporation (Prot #SHP-141-003 // Prot #SHP-141-003)